{"id":283,"date":"2024-12-10T13:22:53","date_gmt":"2024-12-10T21:22:53","guid":{"rendered":"https:\/\/www.leapfrog.bio\/?p=283"},"modified":"2024-12-10T13:24:19","modified_gmt":"2024-12-10T21:24:19","slug":"leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research","status":"publish","type":"post","link":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/","title":{"rendered":"Leapfrog Bio pr\u00e9sente une nouvelle mutation g\u00e9n\u00e9tique sensibilisante associ\u00e9e aux inhibiteurs de BET ainsi que les plans de d\u00e9veloppement clinique de son principal candidat-m\u00e9dicament lors de la conf\u00e9rence sp\u00e9ciale de l\u2019AACR sur la recherche en cancer"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1352px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><em>La plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) de Leapfrog Bio a mis en \u00e9vidence un lien cliniquement significatif entre le g\u00e8ne EP300 et les inhibiteurs des prot\u00e9ines \u00e0 bromodomaine et \u00e0 domaine extra-terminal (BET)<\/em><\/p>\n<p><em>La pr\u00e9sentation d\u00e9crit la d\u00e9couverte, la caract\u00e9risation et le plan de d\u00e9veloppement clinique de LFB190 de Leapfrog Bio pour le traitement de tumeurs solides associ\u00e9es \u00e0 la perte de fonction du g\u00e8ne EP300.<\/em><\/p>\n<p><strong>San Mateo (Californie), le 10 d\u00e9cembre 2024 (GLOBE NEWSWIRE)<\/strong> \u2014 Leapfrog Bio, une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique sp\u00e9cialis\u00e9e dans l\u2019identification de nouvelles th\u00e9rapies pour des mutations oncog\u00e9niques difficiles \u00e0 cibler, a annonc\u00e9 aujourd\u2019hui que Tomas Babak, Ph. D., directeur scientifique de la soci\u00e9t\u00e9, pr\u00e9sentera des donn\u00e9es d\u00e9montrant que la plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) de Leapfrog Bio a mis en \u00e9vidence un lien cliniquement significatif entre le g\u00e8ne EP300 et les inhibiteurs des prot\u00e9ines \u00e0 bromodomaine et \u00e0 domaine extra-terminal (BET).\n\nLa pr\u00e9sentation, intitul\u00e9e \u00ab EP300 loss of function is a pan-cancer sensitizer to BET inhibition \u00bb, aura lieu lors de la conf\u00e9rence sp\u00e9ciale de l\u2019AACR sur la recherche en cancer, \u00e0 Toronto (Canada), et portera sur la d\u00e9couverte, la caract\u00e9risation et le plan de d\u00e9veloppement clinique de l\u2019inhibiteur de BET LFB190 de Leapfrog Bio pour le traitement de tumeurs solides associ\u00e9es \u00e0 une perte de fonction du g\u00e8ne EP300.<\/p>\n<p>La perte du contr\u00f4le transcriptionnel est une caract\u00e9ristique fondamentale du cancer et peut jouer un r\u00f4le cl\u00e9 dans son apparition et sa progression. Les prot\u00e9ines BET r\u00e9gulent l\u2019expression de nombreux g\u00e8nes et voies associ\u00e9s au cancer; plusieurs mol\u00e9cules ciblant cette famille de prot\u00e9ines ont \u00e9t\u00e9 \u00e9valu\u00e9es dans des essais cliniques de phases pr\u00e9coces, mais ont montr\u00e9 une efficacit\u00e9 limit\u00e9e en monoth\u00e9rapie.\n\nApr\u00e8s avoir r\u00e9alis\u00e9 des centaines de criblages pharmacog\u00e9n\u00e9tiques \u00e0 l\u2019aide de sa plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx), Leapfrog Bio a mis en \u00e9vidence une interaction entre l\u2019inhibition des prot\u00e9ines BET et la perte de fonction (LOF) du g\u00e8ne EP300, d\u2019une importance comparable \u00e0 celle de l\u2019axe PARP\u2013BRCA1\/HRD.\n\nLa soci\u00e9t\u00e9 estime \u00e9galement avoir identifi\u00e9 le m\u00e9canisme d\u2019action de cette relation de l\u00e9talit\u00e9 synth\u00e9tique entre l\u2019inhibition des prot\u00e9ines BET et la perte de fonction du g\u00e8ne EP300.<\/p>\n<p>\u00ab Nous avons \u00e9t\u00e9 tr\u00e8s satisfaits d\u2019identifier cette interaction cl\u00e9, compte tenu de l\u2019ampleur des travaux de recherche consacr\u00e9s aux inhibiteurs de BET \u00bb, a d\u00e9clar\u00e9 Tomas Babak, Ph. D., directeur scientifique de Leapfrog Bio. \u00ab La mise en \u00e9vidence d\u2019une interaction forte entre les prot\u00e9ines BET et le g\u00e8ne EP300 mut\u00e9 entra\u00eenant une perte de fonction \u2014 ainsi que du m\u00e9canisme qui la sous-tend \u2014 gr\u00e2ce \u00e0 la plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) constitue une validation importante de la capacit\u00e9 de la plateforme \u00e0 identifier des th\u00e9rapies pour des cancers auparavant difficiles \u00e0 cibler, associ\u00e9s \u00e0 des mutations avec perte de fonction.\n\nLes deux tiers des cancers sont li\u00e9s \u00e0 des mutations de g\u00e8nes suppresseurs de tumeurs, comme c\u2019est le cas pour EP300, et pourtant moins de 1 % de ces g\u00e8nes avec perte de fonction ont fait l\u2019objet d\u2019approches th\u00e9rapeutiques \u00e0 ce jour. Gr\u00e2ce \u00e0 la plateforme de Leapfrog Bio, nous sommes en mesure d\u2019identifier de fa\u00e7on r\u00e9p\u00e9t\u00e9e des candidats th\u00e9rapeutiques r\u00e9pondant aux besoins non satisfaits des patients atteints de cancers associ\u00e9s \u00e0 des mutations avec perte de fonction. \u00bb<\/p>\n<p>Le principal candidat de Leapfrog, LFB190, exploite la relation entre l\u2019inhibition des prot\u00e9ines BET et les mutations avec perte de fonction (LOF) du g\u00e8ne EP300. Le compos\u00e9, pr\u00eat pour la phase 2, a d\u00e9j\u00e0 fait l\u2019objet d\u2019\u00e9tudes cliniques avant les travaux de Leapfrog, et une dose recommand\u00e9e pour la phase 2 a \u00e9t\u00e9 \u00e9tablie.<\/p>\n<p>Greg Vontz, chef de la direction de Leapfrog Bio, a ajout\u00e9 : \u00ab Cette d\u00e9couverte d\u00e9montre la capacit\u00e9 de la plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) \u00e0 mettre au jour des solutions th\u00e9rapeutiques potentielles pour les quelque 10 millions de patients atteints de cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF). Nous avons d\u00e9pos\u00e9 des demandes de propri\u00e9t\u00e9 intellectuelle li\u00e9es \u00e0 cette d\u00e9couverte et pr\u00e9parons actuellement l\u2019entr\u00e9e de LFB190 en phase 2 dans les cancers du poumon, du c\u00f4lon et de la vessie en 2025. \u00bb<\/p>\n<p><strong>\u00c0 propos de Leapfrog Bio<\/strong><\/p>\n<p>Leapfrog Bio est une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique qui acc\u00e9l\u00e8re le d\u00e9veloppement de m\u00e9dicaments contre le cancer en identifiant des mol\u00e9cules d\u00e9j\u00e0 en phase clinique pouvant \u00eatre repositionn\u00e9es comme th\u00e9rapies cibl\u00e9es pour des cancers associ\u00e9s \u00e0 des mutations conductrices difficiles \u00e0 cibler.\n\nSon principal programme consiste en un essai de preuve de concept de phase 2 \u00e9valuant une petite mol\u00e9cule dans trois cancers solides pr\u00e9sentant une mutation g\u00e9n\u00e9tique avec perte de fonction fr\u00e9quente, pour laquelle il n\u2019existe actuellement aucune option th\u00e9rapeutique cibl\u00e9e.\n\nLa plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) de Leapfrog Bio constitue un syst\u00e8me in vitro reproductible et \u00e9volutif permettant d\u2019identifier des m\u00e9dicaments \u00e0 petites mol\u00e9cules existants pouvant \u00eatre d\u00e9velopp\u00e9s pour traiter des cancers li\u00e9s \u00e0 des mutations avec perte de fonction, avec une forte probabilit\u00e9 de succ\u00e8s clinique.\n\nCette plateforme, valid\u00e9e en clinique, est d\u00e9crite dans l\u2019article \u00e9valu\u00e9 par des pairs intitul\u00e9 \u00ab Pharmacogenomic Discovery of Genetically Targeted Cancer Therapies Optimized Against Clinical Outcomes \u00bb, publi\u00e9 dans la revue npj Precision Oncology (Nature Portfolio). Pour en savoir plus, visitez www.leapfrog.bio.<\/p>\n<p>Relations avec les m\u00e9dias :<br \/>\nJanine McCargo<br \/>\n6 Degrees<br \/>\njmccargo@6degreespr.com<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-283","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Leapfrog Bio\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T21:22:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T21:24:19+00:00\" \/>\n<meta name=\"author\" content=\"leapfrogbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"leapfrogbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\"},\"author\":{\"name\":\"leapfrogbio\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\"},\"headline\":\"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research\",\"datePublished\":\"2024-12-10T21:22:53+00:00\",\"dateModified\":\"2024-12-10T21:24:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\"},\"wordCount\":923,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\",\"url\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\",\"name\":\"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#website\"},\"datePublished\":\"2024-12-10T21:22:53+00:00\",\"dateModified\":\"2024-12-10T21:24:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.leapfrog.bio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.leapfrog.bio\/#website\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"name\":\"Leapfrog Bio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.leapfrog.bio\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\",\"name\":\"Leapfrog Bio\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"contentUrl\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"width\":510,\"height\":90,\"caption\":\"Leapfrog Bio\"},\"image\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\",\"name\":\"leapfrogbio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"caption\":\"leapfrogbio\"},\"sameAs\":[\"https:\/\/www.leapfrog.bio\"],\"url\":\"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/","og_locale":"fr_CA","og_type":"article","og_title":"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio","og_url":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/","og_site_name":"Leapfrog Bio","article_published_time":"2024-12-10T21:22:53+00:00","article_modified_time":"2024-12-10T21:24:19+00:00","author":"leapfrogbio","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"leapfrogbio","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#article","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/"},"author":{"name":"leapfrogbio","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3"},"headline":"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research","datePublished":"2024-12-10T21:22:53+00:00","dateModified":"2024-12-10T21:24:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/"},"wordCount":923,"commentCount":0,"publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/","url":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/","name":"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research - Leapfrog Bio","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/#website"},"datePublished":"2024-12-10T21:22:53+00:00","dateModified":"2024-12-10T21:24:19+00:00","breadcrumb":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-presents-novel-genetic-sensitizing-mutation-linked-to-bet-inhibitors-and-clinical-development-plans-for-lead-product-candidate-at-the-aacr-special-conference-in-cancer-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.leapfrog.bio\/"},{"@type":"ListItem","position":2,"name":"Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research"}]},{"@type":"WebSite","@id":"https:\/\/www.leapfrog.bio\/#website","url":"https:\/\/www.leapfrog.bio\/","name":"Leapfrog Bio","description":"","publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.leapfrog.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.leapfrog.bio\/#organization","name":"Leapfrog Bio","url":"https:\/\/www.leapfrog.bio\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/","url":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","contentUrl":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","width":510,"height":90,"caption":"Leapfrog Bio"},"image":{"@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3","name":"leapfrogbio","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","caption":"leapfrogbio"},"sameAs":["https:\/\/www.leapfrog.bio"],"url":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"leapfrogbio","author_link":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"},"_links":{"self":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/comments?post=283"}],"version-history":[{"count":2,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/283\/revisions"}],"predecessor-version":[{"id":285,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/283\/revisions\/285"}],"wp:attachment":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/media?parent=283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/categories?post=283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/tags?post=283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}